IQVIA Holdings Inc. (NYSE:IQV) Shares Purchased by Otter Creek Advisors LLC

Otter Creek Advisors LLC boosted its stake in shares of IQVIA Holdings Inc. (NYSE:IQV – Get Rating) by 24.1% in the 1st quarter, HoldingsChannel.com reports. The firm owned 21,228 shares of the medical research company’s stock after buying an additional 4,124 shares during the quarter. IQVIA accounts for 2.0% of Otter Creek Advisors LLC’s investment portfolio, making the stock its 10th biggest position. Otter Creek Advisors LLC’s holdings in IQVIA were worth $4,908,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Banco Santander S.A. raised its stake in IQVIA by 55.0% in the first quarter. Banco Santander S.A. now owns 72,470 shares of the medical research company’s stock valued at $16,756,000 after buying an additional 25,716 shares during the period. Andesa Financial Management Inc. raised its stake in IQVIA by 9.4% in the first quarter. Andesa Financial Management Inc. now owns 1,228 shares of the medical research company’s stock valued at $284,000 after buying an additional 106 shares during the period. Lincoln National Corp raised its stake in IQVIA by 12.3% in the first quarter. Lincoln National Corp now owns 3,899 shares of the medical research company’s stock valued at $901,000 after buying an additional 428 shares during the period. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. raised its stake in IQVIA by 9.4% in the first quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 100,138 shares of the medical research company’s stock valued at $23,153,000 after buying an additional 8,634 shares during the period. Finally, M&T Bank Corp raised its stake in IQVIA by 8.5% in the first quarter. M&T Bank Corp now owns 114,197 shares of the medical research company’s stock valued at $26,402,000 after buying an additional 8,955 shares during the period. 87.12% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

IQV has been the topic of a number of recent research reports. StockNews.com lowered IQVIA from a “buy” rating to a “hold” rating in a research note on Wednesday, July 13th. SVB Leerink initiated coverage on IQVIA in a research note on Friday, July 15th. They set an “outperform” rating and a $256.00 target price on the stock. Guggenheim increased their target price on IQVIA to $246.00 in a research note on Friday, July 22nd. Wells Fargo & Company lowered IQVIA from an “overweight” rating to an “equal weight” rating and lowered their target price for the stock from $290.00 to $235.00 in a research note on Monday, April 25th. Finally, Evercore ISI increased their target price on IQVIA from $265.00 to $275.00 in a research note on Friday, July 22nd. Two equities research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. According to MarketBeat, IQVIA has an average rating of “Moderate Buy” and a consensus price target of $274.44.

IQVIA Price Performance

Shares of IQV stock traded up $0.40 during trading hours on Friday, reaching $234.74. The company’s stock had a trading volume of 678,106 shares, compared to its average volume of 982,322. The firm’s 50 day simple moving average is $216.94 and its 200-day simple moving average is $223.66. The company has a market capitalization of $43.78 billion, a price-to-earnings ratio of 39.19, a PEG ratio of 2.14 and a beta of 1.32. IQVIA Holdings Inc. has a fifty-two week low of $194.67 and a fifty-two week high of $285.61. The company has a quick ratio of 0.96, a current ratio of 0.96 and a debt-to-equity ratio of 2.36.

IQVIA (NYSE:IQV – Get Rating) last released its quarterly earnings data on Thursday, July 21st. The medical research company reported $2.44 earnings per share for the quarter, beating the consensus estimate of $2.22 by $0.22. IQVIA had a return on equity of 30.21% and a net margin of 8.21%. The company had revenue of $3.54 billion for the quarter, compared to the consensus estimate of $3.49 billion. During the same quarter last year, the business posted $1.94 EPS. IQVIA’s revenue for the quarter was up 3.0% on a year-over-year basis. Sell-side analysts forecast that IQVIA Holdings Inc. will post 9.42 earnings per share for the current year.

IQVIA Company Profile

(Get Rating)

IQVIA Holdings Inc provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.